Medication Use Evaluation for Enoxaparin in Hospitalized COVID-19 Patients
1 other identifier
observational
400
1 country
1
Brief Summary
Retrospective chart review to be conducted at Methodist Richardson Medical Center (MRMC) in Richardson, TX. All adult patients hospitalized with COVID-19 on enoxaparin for DVT prophylaxis will be included. Collected data will be analyzed to determine the safety and effectiveness of the varying enoxaparin doses, and results will be presented at the American Society of Health-System Pharmacists Midyear conference in December 2022.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2021
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 17, 2021
CompletedFirst Submitted
Initial submission to the registry
February 3, 2022
CompletedFirst Posted
Study publicly available on registry
February 7, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 22, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
July 22, 2025
CompletedJuly 28, 2025
July 1, 2025
3.7 years
February 3, 2022
July 23, 2025
Conditions
Outcome Measures
Primary Outcomes (9)
Enoxaparin dose (appropriate for kidney function)
Enoxaparin dose
2021-2022
Charlson comorbidity index (CCI) score
(CCI) score
2021-2022
Padua prediction score for risk of VTE
Padua prediction score
2021-2022
IMPROVE [International Medical Prevention Registry on VTE] bleeding risk assessment score
IMPROVE \[International Medical Prevention Registry on VTE\] bleeding risk assessment score
2021-2022
ICU status
ICU status
2021-2022
Number of thromboembolic events
Number of thromboembolic events
2021-2022
Length of stay
Days
2021-2022
Readmissions for DVT and/or PE
Readmissions for DVT and/or PE
2021-2022
In-hospital mortality with associated DVT or PE
In-hospital mortality with associated DVT or PE
2021-2022
Secondary Outcomes (2)
Bleeding events
2021-2022
Type of bleeding event
2021-2022
Eligibility Criteria
Patients age 18 years or older hospitalized with COVID-19 on prophylactic/non-therapeutic enoxaparin from January 1, 2021 to January 31, 2021 Patients that do not have any other indication for use of enoxaparin (i.e., active DVT/PE, atrial fibrillation, etc.)
You may qualify if:
- Effectiveness of intermediate-intensity vs standard prophylactic enoxaparin regimens on preventing DVT and/or PE in patients with COVID-19, measured using the following variables:
- Enoxaparin dose (appropriate for kidney function)
- Charlson comorbidity index (CCI) score
- Padua prediction score for risk of VTE
- IMPROVE \[International Medical Prevention Registry on VTE\] bleeding risk assessment score
- ICU status
- Number of thromboembolic events
- Length of stay
- Readmissions for DVT and/or PE
- In-hospital mortality with associated DVT or PE
You may not qualify if:
- Safety of intermediate-intensity vs standard prophylactic enoxaparin regimens in patients with COVID-19, measured using the following variables:
- Bleeding events
- Type of bleeding event
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Methodist Richardson Medical Center
Richardson, Texas, 75082, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Betina Daniel, PharmD
Methodist
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 3, 2022
First Posted
February 7, 2022
Study Start
November 17, 2021
Primary Completion
July 22, 2025
Study Completion
July 22, 2025
Last Updated
July 28, 2025
Record last verified: 2025-07